Question-and-Answer SessionSo maybe bigger picture, just with respect to the peptide platform, I think a lot of investors are looking for kind of -- I think you guys are valued pretty much on the assets and self, maybe help us with kind of your investments in the platform itself, how you view this as a renewable resource and that's something that I think you'll get greater value for going forward.Dinesh PatelCEO, President, Secretary & Director Well, first of all, thanks for inviting us. It's a pleasure to ...

89Bio (ETNB) Conference September 03, 2025 11:15 AM ET Speaker0welcome to the next session of the Citi Biopharma back to school event. So my name is Jeff Mecham. I'm a senior biopharma analyst. Have my team with me as well. Our next session is eighty nine Bio, and we have Rowan Peleker, CEO and Ryan Martin, CFO.So guys, welcome. Thank you for coming.Speaker1Great to be here, Jeff. Good to see you again.Speaker0Good to see you. Well, let's just kick it off with a bit of a kind of discussion of the NASH space ...

限售股上市流通概况 - 上海赛伦生物技术股份有限公司首次公开发行限售股将于2025年9月11日上市流通，涉及限售股数量63,848,000股，占公司总股本的59.00% [1][2] - 本次限售股原锁定期为36个月，因触发延长锁定期承诺条件，锁定期额外延长6个月 [2][5] - 限售股股东包括控股股东、实际控制人赵爱仙、范志和、范铁炯，持股5%以上股东上海置源投资有限公司，以及员工持股平台上海赛派投资合伙企业 [2][9] 限售股形成及股本变动 - 公司于2022年3月11日在科创板上市，首次公开发行27,060,000股，发行后总股本为108,220,000股，其中有限售条件流通股占比22.88% [1] - 自限售股形成至今，公司未发生因利润分配或公积金转增导致的股本数量变化 [2] 股东承诺内容 - 控股股东及实际控制人承诺锁定期满后两年内减持价格不低于发行价，且若上市后6个月内股价连续20日低于发行价，锁定期自动延长6个月 [3][4][5] - 股东上海置源投资有限公司及上海赛派投资合伙企业均承诺锁定期36个月，并遵守与控股股东相同的减持价格和锁定期延长条款 [6][7][8][9] - 所有股东均承诺若违反上述条款将承担法律责任，且未对其他限售股流通安排作出特别承诺 [5][8][9] 资金占用及合规性 - 截至核查意见出具日，公司不存在控股股东及其关联方占用资金的情况 [10] - 保荐机构方正证券认为本次限售股上市流通符合科创板相关法律法规及股东承诺要求 [10][11]

Vertex Pharmaceuticals (VRTX) FY 2025 Conference September 03, 2025 11:00 AM ET Speaker0Great. Thank you very much for joining us today. It's right before the lunch sessionSpeaker1probably. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I'm joined by Vertex team today. We have Suzy Lisa, Head of Investor Relations, and we have Manisha Pai. She's Executive Director, Investor Relations at Vertex.Thank you very much for being here.Speaker2Thanks for having us. Super happy.S ...

Avidity Biosciences (RNA) 2025 Conference September 03, 2025 10:20 AM ET Company ParticipantsSarah Boyce - President & CEOSteve Hughes - Chief Medical OfficerConference Call ParticipantsEric Schmidt - Biotechnology AnalystNone - AnalystEric SchmidtGood morning once again, everyone.My name is Eric Schmidt. I'm one of the Cantor analysts. I am delighted to host our next session with AVIDITY Biosciences and also delighted to welcome two of the company's senior executives. We have with us today Sarah Boyce who' ...

股权激励计划 - 公司于2025年9月3日向合资格参与者授出843,000份购股权及3,282,000股股份奖励 [1] - 股权激励依据2020年11月23日采纳的购股权计划及股份奖励计划实施 [1] - 授出方案须待承授人接纳后方可生效 [1]

Rhythm Pharmaceuticals (RYTM) FY 2025 Conference September 03, 2025 09:30 AM ET Speaker0All right, everyone, I think we'll get started here with the next fireside. Again, my name is Derek Archuleta. I'm one of the Senior Biotech Analysts here at Wells Fargo. Very excited to have Rhythm Pharmaceuticals here for our next discussion. We have David Meeker, CEO from the company. David, great to see you. Continuation from our conversation this morning on the breakfast meeting. Maybe just to start out, kind of giv ...

大宗交易情况 - 9月3日大宗交易成交量12.90万股，成交金额499.88万元，成交价38.75元，较当日收盘价折价10.01% [2] - 买方为机构专用席位，卖方为中国国际金融股份有限公司上海分公司 [2] - 近3个月累计发生42笔大宗交易，合计成交金额2.43亿元 [3] 股价及资金表现 - 当日收盘价43.06元，单日上涨5.36%，日换手率3.61%，成交额6.46亿元 [3] - 近5日累计上涨11.70%，但同期主力资金净流出5047.54万元 [3] - 当日主力资金净流入1805.34万元 [3] 融资余额变化 - 最新融资余额1.31亿元，近5日减少4367.76万元，降幅达25.00% [4] 机构评级与目标价 - 近5日共有3家机构给予评级，东方证券9月3日研报给出最高目标价47.30元 [4]

Candel Therapeutics (CADL) Conference September 03, 2025 09:00 AM ET Company ParticipantsPaul Peter Tak - President, CEO & DirectorYigal Nochomovitz - DirectorCharles Schoch - CFOPaul Peter TakGood morning.Yigal NochomovitzOkay.Okay. All right, we can go. All right, is it working? I see a red color here. It's on? Okay.Paul Peter TakIt's on here as well.Yigal NochomovitzYeah, good. Great.Paul Peter TakIt's good.Yigal NochomovitzAll right. Welcome everyone to day two of Citi's Back to School Summit. We're all ...

enGene Holdings (ENGN) FY 2025 Conference September 03, 2025 08:45 AM ET Speaker0Late, in terms of helping the profile of detalimogene voraplasmid. Now, those protocol amendments were effectively implemented near the end of last year. As we were enrolling patients, we would like to have a reasonable cohort, reasonable size cohort of patients, at least three to six months' data where you could see the impact of those changes. That's what we're really waiting for. This morning, we shared our guidance that in ...